-
Dec 2, 2024 | 
nature.com | Joseph McGuirk |Leland Metheny III |Mark Litzow |Scott Rowley |Roni Tamari |Hillard M. Lazarus
Correction to: Bone Marrow Transplantation https://doi.org/10.1038/s41409-023-02068-3, published online 08 August 2023Following the publication of this article, the authors would like to add an additional reference as below to add context on the original discovery of PLX-R18's proposed therapeutic capabilities:16. Gaberman E, Pinzur L, Levdansky L, Tsirlin M, Nete~ N, Aberman Z, et al.
-
Nov 5, 2024 | 
nature.com | Niveditha Ravindra |Zoe Bayliss Wong |Zoë C Wong |Jeffery J. Auletta |Yi-Bin Chen |Steven M. Devine | +4 more
AbstractMeasurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important prognostic marker, but detection methodology requires optimization. Persistence of mutated NPM1 or FLT3-ITD in the blood of adult patients with AML in first complete remission (CR1) prior to allogeneic hematopoietic cell transplant (alloHCT) associates with increased relapse and death after transplant.
-
Nov 1, 2024 | 
targetedonc.com | Mark Litzow
Mark R. Litzow, MD, professor of medicine in the Division of Hematology at the Mayo Clinic, discusses the findings from the ECOG-ACRIN E1910 trial (NCT02003222) which evaluated blinatumomab (Blincyto) added to chemotherapy vs chemotherapy alone in B-cell precursor acute lymphoblastic leukemia (B-ALL).
-
Oct 26, 2024 | 
targetedonc.com | Mark Litzow
Mark R. Litzow, MD, professor of medicine in the Division of Hematology at the Mayo Clinic, discusses the methods and design from the ECOG-ACRIN E1910 trial (NCT02003222). In the study, experts evaluated blinatumomab (Blincyto) when added to chemotherapy vs chemotherapy alone for the treatment of patients with B-cell precursor acute lymphoblastic leukemia (ALL). Transcription:0:09 | In my presentation, I presented a study that I had the privilege of leading.
-
Oct 24, 2024 | 
nature.com | Niveditha Ravindra |Zoe Bayliss Wong |Zoë C Wong |Jeffery J. Auletta |Yi-Bin Chen |Steven M. Devine | +4 more
AbstractRoutine genetic profiling of acute myeloid leukemia (AML) at initial diagnosis has allowed subgroup specific prognostication, drug development, and clinical management strategies. The optimal approach for treatment response assessment for AML subgroups has not yet however been determined.
-
Oct 17, 2024 | 
nature.com | Niveditha Ravindra |Zoë C Wong |Jeffery J. Auletta |Steven M. Devine |Mark Litzow |Partow Kebriaei | +2 more
To the Editor:High relapse rates for patients despite potentially curative allogeneic hematopoietic cell transplant (alloHCT) remain a critical issue in acute myeloid leukemia (AML). Next-generation sequencing (NGS) represents a promising modality for measurable residual disease (MRD) testing in patients with AML, but the appropriate targets for monitoring must be defined [1,2,3,4,5,6,7].
-
Sep 17, 2024 | 
targetedonc.com | Mark Litzow
Treatments have produced notable improvements in outcomes in the past few years with the advent of pediatric intensive regimens for adolescents and young adults, use of minimal residual disease (MRD) for risk assessment, and introduction of potent immunotherapeutic agents including blinatumomab (Blincyto), inotuzumab ozogamicin (IO; Besponsa), and chimeric antigen receptor (CAR) T-cell therapies tisagenlecleucel (Kymriah) and brexucabtagene autoleucel (brexu-cel; Tecartus).
-
Feb 17, 2024 | 
onlinelibrary.wiley.com | Mark Litzow
• , , , , . The landscape of bispecific T cell engager in cancer treatment . Biomarker Res. ; ( ): - . doi:10.1186/s40364-021-00294-9• , , , et al. Targeted therapy with the T-cell - engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival . J Clin Oncol. ; ( ): - . doi:10.1200/JCO.2010.32.7270• , , , et al.
-
Nov 7, 2023 | 
nature.com | Guillermo Garcia-Manero |Nikolai A. Podoltsev |Megan Othus |John Pagel |David A. Rizzieri |Guido Marcucci | +7 more
AbstractPrior experience indicated that use of higher doses of cytarabine during induction for acute myeloid leukemia (AML) with a histone deacetylase inhibitor resulted in high response rates. S1203 was a randomized multicenter trial for previously untreated patients aged 18–60 with AML which compared daunorubicin and cytarabine (DA), idarubicin with higher dose cytarabine (IA) and IA with vorinostat (IA + V). The primary endpoint was event free survival (EFS).
-
Aug 8, 2023 | 
nature.com | Joseph McGuirk |Mark Litzow |Scott Rowley |Roni Tamari |Hillard M. Lazarus |Leland Metheny III
AbstractPersistent cytopenia in the post-hematopoietic cell transplantation (HCT) setting can occur despite adequate engraftment of donor cells. PLX-R18, a placental-derived mesenchymal-like cell product, is expanded ex vivo in a 3-dimensional environment. PLX-R18 cells secrete a large array of hematopoietic factors, which promote regeneration, maturation, and differentiation of hematopoietic cells and stimulate their migration to peripheral blood.
